The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VECTORMUNE® HVT-NDV + Rispens
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saude Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulinia - SP
Sao Paulo, Brazil
Vectormune HVT-NDV & Rispens is vaccine against Newcastle
disease (ND) and Marek's Disease (MD; Rispens). The vaccine
contains modified Turkey Herpesvirus (Marek's disease vaccine;
serotype 3), expressing fusion protein from Newcastle disease
virus, and an attenuated strain of Gallid alphaherpesvirus
2 (Marek's Disease virus) serotype 1.
Kindly note that only the Turkey Herpesvirus was modified (the
Marek's Disease Virus serotype 1 was not).
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Meleagrid alphaherpesvirus 1 - Turkey herpesvirus, Meleagrid herpesvirus 1
Turkey Herpesvirus: wild-type; strain FC126
- Cell transfection and recombination
Beta-actin gene promoter
SV40 poly-adenylation signal
Genetic elements from p45/p46PecF introduced into Turkey
The recombinant virus contains an expression cassette located in
the intergenic region between genes UL45 and UL46 Turkey
Herpesvirus (HVT). The recombinant virus was created by
transfecting chick embryo fibroblast cells with wild-type HVT
strain FC126 and the plasmid vector p45/46PecF. During viral
packaging, recombination of the genetic material occurred due to
the homologous sequences of UL45 and UL46 flanking the expression
cassette in the plasmid vector and recombinant viruses were
During viral transcription, the Cytomegalovirus enhancer promotes
strong transcription from the chicken (Gallus gallus)
beta-actin promoter and transcribes the Newcastle disease virus
fusion protein (Protein F) before terminating at the Macaca
mulatta polyomavirus 1 poly-adenylation signal.
The recombinant virus is sufficient to create immunity to Newcastle
disease virus and Merek's disease virus (Gallid
alphaherpesvirus 2). A second attenuated strain of the
virulent Merek's Disease virus has been included to convey broader
immunity against Merek's disease virus.
The expression of Protein F was confirmed using Southern blotting.
- Production of medical or pharmaceutical compounds (human or animal)